NDAINTRAVENOUSPOWDERPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
RECARBRIO (imipenem anhydrous, cilastatin, and relebactam anhydrous) by Merck & Co. is dipeptidase inhibitors [moa]. First approved in 2019.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RECARBRIO is a fixed-dose combination IV antibiotic containing imipenem, cilastatin, and relebactam—a novel β-lactamase inhibitor that restores imipenem activity against resistant gram-negative pathogens. It is indicated for complicated intra-abdominal and urinary tract infections caused by susceptible organisms, including carbapenem-resistant Enterobacteriaceae. The relebactam component inhibits serine β-lactamases, preventing degradation of the imipenem core.
$0.001BPart D
Peak6.6 years to LOEEarly-stage peak phase with minimal Part D penetration suggests limited current commercial scale; career growth depends on hospital formulary adoption and infectious disease market expansion.
Mechanism of Action
Dipeptidase Inhibitors
Pharmacologic Class:
Renal Dehydropeptidase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RECARBRIO offers deep expertise in hospital-based antibiotic marketing, resistant pathogen management, and health economics—critical skills in the high-stakes infectious disease space. The product's niche position and limited Part D footprint suggest a specialized, high-touch commercial model ideal for professionals targeting hospital/IDN careers and infectious disease expertise.
Brand Manager
Worked on RECARBRIO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.